Nice | Idelalisib for treating chronic lymphocytic leukaemia

15th February 2016 by Louise Hudman

Nice | Idelalisib for treating chronic lymphocytic leukaemia

This is a new guideline from NICE on idelalisib use in chronic lymphocytic leukaemia. Idelalisib is likely to be secondary care prescribed, but I felt it was worthwhile knowing about as it is a new type of drug and we will probably see patients on it.

Idelalisib is an oral drug and will be used in combination with rituximab infusions. It is a ‘first-in-class’ drug which inhibits enzymes involved in cell proliferation, death and migration.

Side-effects

Among other side-effects, it can raise transaminases, triglycerides and can cause neutropenia.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"A must-have for any GP locum.

I have used NASGP website since I started locuming three years ago. It caters for all my locum needs, and I found LocumDeck particularly useful for bookings and invoicing. The automatically-generated invoices and pension forms save me countless hours of admin time every month, and the recently introduced e-signed forms are brilliant.

The assistance I have received has always been quick and helpful. The forums and updates have also kept me in the loop with important issues which may affect my practice.

I cannot recommend this website enough. "

Dr Suzanne Gaskell

Dr Suzanne Gaskell

See the full list of features within our NASGP membership plans

Membership